We performed targeted DNA-based next-generation sequencing (NGS) evaluating all exons of 479 cancer genes and select introns and upstream regulatory regions of 47 genes, including genes critical for glioma diagnosis, e.g., IDH1, IDH2, EGFR, PDGFRA, MET, FGFR1, FGFR2, FGFR3, NF1, BRAF, PIK3CA, PIK3R1, PTEN, CDKN2A, CDK4, CDK6, RB1, TP53, MDM2, MDM4, H3F3A, HIST1H3B, CIC, FUBP1, ATRX, and TERT (including the promoter region) [17,18]. The gene discussed is TP53; the disease is central nervous system cancer.